Middle East & North Africa

Schizophrenia Gets a Five-Day Brain-Stimulation Signal
A small sham-controlled trial found substantial short-term symptom improvement after fronto-temporal tDCS in treatment-resistant schizophrenia. The signal is striking. The evidence is still much too small to call it a treatment answer.

Same BMI, different biology: low-cost markers may expose the obesity risk the scale misses

The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome

Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy

MENA’s cardiometabolic crisis is a stability issue

Eight Patients Cannot Solve Alzheimer’s. They Can Tell Us What the Next Trial Must Prove.

Parkinson’s Research Takes Aim at Mitochondrial Failure

Lenacapavir Turns HIV Prevention Into an Access Stress Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
